Stability and solidification of thymol-loaded
self-microemulsifying drug delivery system

k 2024

Stability and solidification of thymol-loaded self-microemulsifying drug delivery system

KOUTNÁ, Gabriela, Jan MUSELÍK, Kateřina KUBOVÁ, Jakub VYSLOUŽIL, David VETCHÝ et. al.

Základní údaje

Originální název

Stability and solidification of thymol-loaded self-microemulsifying drug delivery system

Autoři

KOUTNÁ, Gabriela (203 Česká republika, domácí), Jan MUSELÍK (203 Česká republika, garant, domácí), Kateřina KUBOVÁ (203 Česká republika, domácí), Jakub VYSLOUŽIL (203 Česká republika, domácí), David VETCHÝ (203 Česká republika, domácí), Jan KOTOUČEK (203 Česká republika) a Josef MAŠEK (203 Česká republika)

Vydání

14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 2024

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Farmaceutická fakulta

Klíčová slova anglicky

self-microemulsifying system; thymol; stability; solidification

Štítky

ÚFT

Změněno: 12. 4. 2024 11:26, doc. Mgr. Jan Muselík, Ph.D.

Anotace

V originále

Self-emulsifying drug delivery systems (SEDDS) have gained recognition as a crucial approach to enhancing the bioavailability of poorly water-soluble drugs. Thymol boasts a plethora of biological effects, such as anti-inflammatory, antioxidant, immunomodulatory, and analgesic properties. Thymol is a GRAS candidate for preventing and treating inflammatory bowel diseases. Given their limited bioavailability, thymol presents a promising candidate for inclusion in self-emulsifying systems. Nevertheless, liquid SEDDS pose challenges, including the potential irritation caused by a high surfactant content on the gastrointestinal mucosa, reduced formulation stability, and complexities in handling. Solid SEDDS, conversely, are solidified self-emulsifying formulations achieved by converting liquid SEDDS into self-emulsifying powders or particles. Neusilin® US2 was chosen as the solid carrier for thymol SMEDDS formulation. The optimized T-SMEDDS formulations underwent long-term stability tests, and six months stability was demonstrated. The optimal ratio of T-SMEDDS formulation with the solid carrier Neusilin® US2 was 2:1. In vitro dissolution characteristics was determined using biorelevant media FaSSIF. The release of more than 85% of thymol from the T-SMEEDS formulation within 15 minutes indicates a reasonable presumption for enhanced thymol bioavailability in the biosystem.

Návaznosti

GA22-03187S, projekt VaV

Název: Racionální design částicových polysacharidových systémů pro přívod léčiv s širokým spekterem biologické aktivity k terapii sliznic (Akronym: 22-03187S)

Investor: Grantová agentura ČR, Racionální design částicových polysacharidových systémů pro přívod léčiv s širokým spektrem biologické aktivity k terapii sliznic

Citovat

KOUTNÁ, Gabriela, Jan MUSELÍK, Kateřina KUBOVÁ, Jakub VYSLOUŽIL, David VETCHÝ, Jan KOTOUČEK a Josef MAŠEK. Stability and solidification of thymol-loaded self-microemulsifying drug delivery system. In 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. 2024.

@proceedings{2393304,
   author = {Koutná, Gabriela and Muselík, Jan and Kubová, Kateřina and Vysloužil, Jakub and Vetchý, David and Kotouček, Jan and Mašek, Josef},
   booktitle = {14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology},
   keywords = {self-microemulsifying system; thymol; stability; solidification},
   language = {eng},
   title = {Stability and solidification of thymol-loaded self-microemulsifying drug delivery system},
   year = {2024}
}

TY  - CONF
ID  - 2393304
AU  - Koutná, Gabriela - Muselík, Jan - Kubová, Kateřina - Vysloužil, Jakub - Vetchý, David - Kotouček, Jan - Mašek, Josef
PY  - 2024
TI  - Stability and solidification of thymol-loaded self-microemulsifying drug delivery system
KW  - self-microemulsifying system
KW  - thymol
KW  - stability
KW  - solidification
N2  - Self-emulsifying drug delivery systems (SEDDS) have gained recognition as a crucial approach to enhancing the bioavailability of poorly water-soluble drugs. Thymol boasts a plethora of biological effects, such as anti-inflammatory, antioxidant, immunomodulatory, and analgesic properties. Thymol is a GRAS candidate for preventing and treating inflammatory bowel diseases. Given their limited bioavailability, thymol presents a promising candidate for inclusion in self-emulsifying systems. Nevertheless, liquid SEDDS pose challenges, including the potential irritation caused by a high surfactant content on the gastrointestinal mucosa, reduced formulation stability, and complexities in handling. Solid SEDDS, conversely, are solidified self-emulsifying formulations achieved by converting liquid SEDDS into self-emulsifying powders or particles. Neusilin® US2 was chosen as the solid carrier for thymol SMEDDS formulation. The optimized T-SMEDDS formulations underwent long-term stability tests, and six months stability was demonstrated. The optimal ratio of T-SMEDDS formulation with the solid carrier Neusilin® US2 was 2:1. In vitro dissolution characteristics was determined using biorelevant media FaSSIF. The release of more than 85% of thymol from the T-SMEEDS formulation within 15 minutes indicates a reasonable presumption for enhanced thymol bioavailability in the biosystem.
ER  -

KOUTNÁ, Gabriela, Jan MUSELÍK, Kateřina KUBOVÁ, Jakub VYSLOUŽIL, David VETCHÝ, Jan KOTOUČEK a Josef MAŠEK. Stability and solidification of thymol-loaded self-microemulsifying drug delivery system. In \textit{14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology}. 2024.

Podrobný výpis o publikaci